Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

By afschroeder • October 20, 2025

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Oct 19:101200JCO2502023. doi: 10.1200/JCO-25-02023. Epub ahead of print. PMID: 41109959.

Tags: binimetinib, BRAF, Encorafenib, Hematology/Oncology, Non-small cell lung cancer, Publications

Related Posts

A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program

Bailey AV, Frochen S, Kwan L, Siavoshi M, Haroldsen CL, Shelton JB, Rose B, Maxwell KN, Nickols NG, Yamoah K, Rebbeck TR, Schoen MW, Rettig[...]

Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study

Ji J, Sun CL, Dale W, Cohen HJ, Kim H, Katheria V, Baclig N, Zektser Y, Niknafs A, Margolis S, Lee C, Smith C, Sedrak[...]

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ,[...]